Great Medicine Holdings: Application for Clinical Trial Registration of Prasugrel Hydrochloride Tablets Accepted

Heavy Medicine Holdings announcement, a subsidiary of Heavy Medicine Corporation received the "Acceptance Notice" issued by the National Medical Products Administration for the registration of clinical trials for Hydrochloride Prasugrel Tablets. The original research company of this drug is Daiichi Sankyo Company, and it is used for the prevention of acute coronary syndromes after percutaneous coronary intervention, stable angina, and thrombosis in patients with old myocardial infarction. It is currently marketed in more than 70 countries and regions worldwide, and Heavy Medicine Corporation has invested in introducing the technology and exclusive patent authorization for this drug. By the end of May 2025, Heavy Medicine Corporation submitted an application for domestic production of Hydrochloride Prasugrel Tablets for registration of clinical trials and it has been accepted.